CClinicalTrials.gg
CompletedNCT01586650Updated Feb 15, 2017

Effects of Aerobic Training in Patients With Ankylosing Spondylitis

A Phase 3 interventional study of aerobic training and Stretching exercises in Ankylosing Spondylitis, sponsored by Federal University of São Paulo. Completed at 1 site in Brazil. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2017-02-15.

Sponsored by Federal University of São Paulo · Phase 3, Interventional, and Treatment

Phase
Phase 3
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

This is a randomized controlled trial with blinded assessor on the effects of aerobic exercise (walking)in patients with Ankylosing Spondylitis.

Read the detailed description

Ankylosing Spondylitis (AS) is a systemic inflammatory disease that affects mainly the spine and compromises globally the physical capacity of the patients. Despite new advances in pharmacological therapy, physiotherapy and exercise remain essential in the treatment of AS. However, the literature lacks studies showing which types of exercises are more effective in patients with AS.

This is a randomized controlled trial with the objective is to evaluate the effects of aerobic training on functional capacity, mobility, disease activity, cardiopulmonary capacity and cytokine levels (TNF, IL10, IL6 and IL1) in patients with AS.

The duration of the trial is 24 weeks with the first 12 weeks reserved to exercise programs. The participants will be divided in two groups. The intervention group (IG) will perform walking for 50 minutes plus global stretching 3 times a week for 12 weeks. The control group (CG) will do only stretching exercises 3 times a week for 12 weeks.

02

Conditions studied

  • Ankylosing Spondylitis

Keywords

  • ankylosing spondylitis
  • aerobic exercise
03

In context

Spondylitis

623 studies on the registry are indexed under Spondylitis; 83 are open to participants now.

This study's enrollment of 70 is below the median of 92 across 349 interventional studies indexed under Spondylitis.

Browse Spondylitis studies →

Lead sponsor

Federal University of São Paulo is the lead sponsor of 427 studies on the registry; 22 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Diagnosis of Ankylosing Spondylitis according to New York modified criteria.

    • Stable drug treatment for at least 3 months
    • Sedentary for at least 3 months before randomization
    • Steinbrocker class I/II

Exclusion criteria

Exclusion Criteria:

  • Uncontrolled Systemic Arterial Hypertension and Diabetes mellitus.

    • Ischemic heart disease
    • Clinically significant diseases
    • Orthopedic surgery, such as hip arthroplasty, in the last year.
    • Inability to walk.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
70 participants (actual)

Study arms

  • Experimental
    Aerobic training

    The patients in this arm perform a 50-minute-walking at anaerobic threshold plus stretching exercises 3 times a week for 12 weeks.

    Other: aerobic training · Other: Stretching exercises

  • Placebo comparator
    Stretching exercises

    The control group perform global stretching exercises for approximately 20 minutes 3 times a week for 12 weeks.

    Other: Stretching exercises

Interventions

  • Otheraerobic training

    The intervention comprises fifty minutes of walking at anaerobic threshold plus stretching exercises 3 times a week for 12 weeks.

  • OtherStretching exercises

    Global stretching exercises will be performed for about 20 minutes 3 times a week for 12 weeks with supervision of specialized physiotherapists.

06

What researchers measure

Primary outcomes

  1. Change in BASFI

    Bath Ankylosing Spondylitis Functional Index (BASFI) is a quaestionnaire with 10 questions about functional capacity validated to AS patients. Each question is answered with a visual analogue scale 0-10 cm. Zero means the best, and 10 the worst function.

    Time frame: Baseline, after 6, 12 and 24 weeks.

Secondary outcomes

  1. Change in BASDAI

    Bath Ankylosing Spondylitis Disease Activity Score (BASDAI) is a instrument with 6 questions about disease activity validated to AS patients. The questions comprise the following areas: back pain, peripheral pain, morning stifness, fatigue and enthesitis.

    Time frame: Baseline, after 6, 12 and 24 weeks.

  2. Change in BASMI

    Bath Ankylosing Spondylitis Mobility Index (BASMI) is an instrument that comprises 5 measures of mobility validated to AS patients. The measurements are: cervical rotation, lumbar flexion (Schober's test modified, intermalleolar distance, lumbar side flexion and tragus to wall. The total score is shown in a 0-10 cm visual analogue scale. The low scores represent better mobility.

    Time frame: Baseline, after 6, 12 and 24 weeks.

  3. Change in HAQ-S

    Health Assessment Questionnaire for Spondyloarthritis (HAQ-S)is a questionnaire with 10 domains about functional capacity validated to AS patients. The scores ranges from 0 to 3.

    Time frame: Baseline, after 6, 12 and 24 weeks.

  4. Incremental cardiopulmonary exercise testing protocol by treadmill

    Incremental cardiopulmonary exercise testing protocol by treadmill is used to measure aerobic capacity of the patients.

    Time frame: Baseline and after 12 weeks.

  5. Levels of C reactive protein and erythrocyte rate sedimentation

    CRP and ESR are laboratory methods to evaluate inflammatory response using blood sample.

    Time frame: Baseline, after 6. 12 and 24 weeks

  6. Levels of cytokines- TNF, IL10, IL6 and IL1.

    Cytokines are substances that make part of inflammatory response. The most important cytokines- TNF alpha, IL10, IL6 and IL1 will be measured in serum samples.

    Time frame: Baseline and after 12 weeks.

  7. Change in the Six minute walking test

    The 6-minute walking test is a instrument to evaluate functional capacity. It is performed measuring the distance that the participant is able to walk during 6 minutes.

    Time frame: Baseline, after 6, 12 and 24 weeks.

07

Study locations

1 site
  • Universidade Federal de Sao Paulo
    Sao Paulo, 04039-002, Brazil
08

References and documents

Publications

  • Braun J, van den Berg R, Baraliakos X, Boehm H, Burgos-Vargas R, Collantes-Estevez E, Dagfinrud H, Dijkmans B, Dougados M, Emery P, Geher P, Hammoudeh M, Inman RD, Jongkees M, Khan MA, Kiltz U, Kvien T, Leirisalo-Repo M, Maksymowych WP, Olivieri I, Pavelka K, Sieper J, Stanislawska-Biernat E, Wendling D, Ozgocmen S, van Drogen C, van Royen B, van der Heijde D. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis. 2011 Jun;70(6):896-904. doi: 10.1136/ard.2011.151027. PubMed 21540199 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 15, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01586650
Lead sponsor
Federal University of São Paulo
Collaborators
Fundação de Amparo à Pesquisa do Estado de São Paulo
Responsible party
Martin F Simoes, MD (MD, Federal University of São Paulo) — Principal investigator
First posted
Apr 27, 2012
Start date
Jul 2011
Primary completion
Nov 2012
Completion
Feb 2013
Last update
Feb 15, 2017

Study contacts

Jamil Natour, Prof, MD
study director · Federal University of São Paulo

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion